BioNote Past Earnings Performance
Past criteria checks 0/6
BioNote's earnings have been declining at an average annual rate of -106.7%, while the Biotechs industry saw earnings growing at 9.2% annually. Revenues have been declining at an average rate of 81.2% per year.
Key information
-106.7%
Earnings growth rate
-106.1%
EPS growth rate
| Biotechs Industry Growth | 11.7% |
| Revenue growth rate | -81.2% |
| Return on equity | -1.3% |
| Net Margin | -22.8% |
| Last Earnings Update | 31 Dec 2023 |
Recent past performance updates
No updates
Recent updates
Revenue & Expenses BreakdownBeta
How BioNote makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 31 Dec 23 | 90,081 | -20,497 | 20,070 | 13,405 |
| 30 Sep 23 | 91,102 | -155,974 | 11,283 | 15,563 |
| 30 Jun 23 | 131,976 | -68,973 | 16,431 | 15,967 |
| 31 Mar 23 | 224,641 | 35,725 | 29,411 | 17,548 |
| 31 Dec 22 | 479,657 | 307,798 | 27,924 | 16,138 |
Quality Earnings: A377740 is currently unprofitable.
Growing Profit Margin: A377740 is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: Unable to establish if A377740's year-on-year earnings growth rate was positive over the past 5 years as it has been trading publicly for less than 3 years.
Accelerating Growth: Unable to compare A377740's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: A377740 is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (28.8%).
Return on Equity
High ROE: A377740 has a negative Return on Equity (-1.32%), as it is currently unprofitable.